Adverse events associated with treatment of latent tuberculosis in the general population

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 3, 2011, Pages

  Smith, Benjamin M ^a   Schwartzman, Kevin ^a   Bartlett, Gillian ^b   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; AGED; ARTICLE; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DERMATITIS; DIABETES MELLITUS; DRUG INTOXICATION; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HOSPITAL ADMISSION; HUMAN; KIDNEY DISEASE; LATENT TUBERCULOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT OUTCOME; VOMITING;

EID: 79951986710     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.091824     Document Type: Article

References (24)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. Joint statement of the American Thoracic Society, the Centers for Disease Control and the Council of the Infectious Diseases Society of America. Am J Respir Crit Care Med 2000;161(suppl4, pt 2):S221-47.
2. Long R, Ellis E, editors. Canadian tuberculosis standards. 6th ed. Ottawa (ON): The Canadian Lung Association, Canadian Thoracic Society, Public Health Agency of Canada and Tuberculosis Prevention and Control; 2007.
3. Schwartzman K. Latent tuberculosis: old problem, new priorities. CMAJ 2002;166:759-61. (Pubitemid 34253124)
4. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2007. Atlanta (GA): US Dept of Health & Human Services; 2008.
5. Sorresso DJ, Mehta JB, Harvill LM, et al. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older. A prospective analysis. Chest 1995;108:706-11.
6. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1969;17:28-106.
7. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001. (Pubitemid 8380195)
8. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official statement: hepatotoxicity of antituberculous therapy. Am J Respir Crit Care Med 2006;174:935-52. (Pubitemid 44564795)
9. Comstock GW. Evaluating isoniazid preventive therapy: the need for more data. Ann Intern Med 1981;94:817-9. (Pubitemid 11123386)
10. Riska N. Hepatitis cases in isoniazid treated groups and in a control group. Bull Int Union Tuberc 1976;51:203-8.
11. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993;159:560-4. (Pubitemid 23339480)
12. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-23. (Pubitemid 40994462)
13. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health TB clinic. JAMA 1999;281: 1014-8. (Pubitemid 29143893)
14. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-7. (Pubitemid 37046873)
15. Moulding T. Toxicity associated with isoniazid preventive therapy. JAMA 1999;282:2207-8. (Pubitemid 30002955)
16. Population and dwelling counts, for Canada, provinces, territories and census subdivisions (municipalities), 2006 census. Ottawa (ON). Statistics Canada; 2007.
17. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
18. Tamblyn R, Reid T, Mayo N, et al. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000;53:183-94. (Pubitemid 30151224)
19. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/CDC recommendations - United States 2001. JAMA 2001;286:1445-6.
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
21. Garibaldi RA, Drusin RE, Ferebee SH, et al. Isoniazid-associated hepatitis - report of an outbreak. Am Rev Respir Dis 1972;106:357-64.
22. Black M, Mitchell JR, Zimmerman HJ, et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302.
23. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis: a review of available information. Am Rev Respir Dis 1992;145:494-7.
24. Millard PS, Wilcosky TC, Reade-Christopher SJ, et al. Isoniazid-related fatal hepatitis. West J Med 1996;164:486-91. (Pubitemid 26250847)